| 臺大學術典藏 |
2020-03-05T08:04:03Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Min-Shu Hsieh;Lee M.-R.;Keng L.-T.;Ko J.-C.;Shih J.-Y.; Liang S.-K.; MIN-SHU HSIEH; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:34:21Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; Min-Shu Hsieh; MENG-RUI LEE; LI-TA KENG; JEN-CHANG KO; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-10-04T07:15:44Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T02:56:48Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Li-Ta Keng;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:51:01Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:19Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
SHENG-KAI LIANG; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 中山醫學大學 |
2021 |
Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
|
Su, PY; Su, WW; Hsu, YC; Huang, SP; Yen, HH |
| 國立成功大學 |
2023 |
Real-world experience on intravitreal dexamethasone implant in patients with macular edema scheduled to undergo cataract surgery
|
Lai, C.-C.;Kuo, S.-C. |
| 臺大學術典藏 |
2021-05-06T01:25:13Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; Sun H.-Y.; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; Cheng A.; Ko W.-C.; Cheng S.-H.; CHIEN-CHING HUNG; the Taiwan HIV Study Group |
| 臺大學術典藏 |
2021-08-16T08:36:11Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; Sun H.-Y.; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; ARISTINE CHENG; Ko W.-C.; Cheng S.-H.; Hung C.-C.; the Taiwan HIV Study Group |
| 臺大學術典藏 |
2021-08-20T07:10:55Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; HSIN-YUN SUN; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; Cheng A.; Ko W.-C.; Cheng S.-H.; Hung C.-C.; the Taiwan HIV Study Group |
| 國立成功大學 |
2021 |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou, B.-H.;Sun, H.-Y.;Yang, C.-J.;Syue, L.-S.;Lee, Y.-L.;Tang, H.-J.;Tsai, H.-C.;Lin, C.-Y.;Chen, T.-C.;Lee, C.-Y.;Huang, S.-H.;Liu, C.-W.;Lu, P.-L.;Lin, S.-P.;Wang, N.-C.;Cheng, A.;Ko, W.-C.;Cheng, S.-H.;Hung, C.-C.;Group, the Taiwan HIV Study |
| 嘉南藥理大學 |
2021 |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou, Bo-Huang; Sun, Hsin-Yun; Yang, Chia-Jui; Syue, Ling-Shan; Lee, Yu-Lin; Tang, Hung-Jen; Tsai, Hung-Chin; Lin, Chi-Ying; Chen, Tun-Chieh; Lee, Chun-Yuan; Huang, Sung-Hsi; Liu, Chia-Wei; Lu, Po-Liang; Lin, Shih-Ping; Wang, Ning-Chi; Cheng, Aristine; Ko, Wen-Chien; Cheng, Shu-Hsing; Hung, Chien-Ching |
| 臺大學術典藏 |
2020-03-05T06:05:32Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 臺大學術典藏 |
2020-11-03T12:37:44Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
Li-Kai Tsai;Lin H.-J.;Chua S.-K.;Liao P.-C.;Yang Y.-P.;Chou P.-C.;Lee C.-W.;Lin M.-J.;Chen H.-M.;Yeh J.-T.;Li Y.-H.; LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 臺大學術典藏 |
2021-11-26T05:56:35Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 國立成功大學 |
2018-02 |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
Tsai;Li-Kai;Lin;Huey-Juan;Chua;Su-Kiat;Liao;Pen-Chih;Yang;Yuan-Po;Chou;Ping-Chen;Lee;Chun-Wei;Lin;Mao-Jen;Chen;Hsi-Ming;Yeh;Jung-Tze;Li;Yi-Heng |
| 臺大學術典藏 |
2021-08-15T00:08:17Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni, Marisa; CHIH-HSIN YANG; JIN-YUAN SHIH; Peled, Nir; Smit, Egbert F.; Camidge, D. Ross; Arasada, Rajeswara Rao; Oksen, Dina; Boutmy, Emmanuelle; Stroh, Christopher; Johne, Andreas; Carbone, David P.; Paik, Paul K. |
| 臺大學術典藏 |
2021-11-03T02:33:00Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; Yang J.C.-H.; JIN-YUAN SHIH; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2022-08-10T02:37:40Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; CHIH-HSIN YANG; Shih J.-Y.; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 國立交通大學 |
2019-04-03T06:37:18Z |
Real-World Neuroimaging Technologies
|
McDowell, Kaleb; Lin, Chin-Teng; Oie, Kelvin S.; Jung, Tzyy-Ping; Gordon, Stephen; Whitaker, Keith W.; Li, Shih-Yu; Lu, Shao-Wei; Hairston, W. David |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Real-World or Controlled Clinical Trial Data in Real-World Practice
|
Chih-Hsin Yang;Wu T.-H; Wu T.-H; CHIH-HSIN YANG |
